Implantable medical device for identifying and managing intrinsic reentrant tachycardia

• US 8,086,308 B2
• Filed: 06/23/2008
• Issued: 12/27/2011
• Est. Priority Date: 06/27/2007
• Status: Active Grant

• Current Assignee: Pacesetter Incorporated (Abbott Laboratories Incorporated)
• Original Assignee: Pacesetter Incorporated (Abbott Laboratories Incorporated)
• Inventors: Levine, Paul A.
• Primary Examiner(s): Layno, Carl H.
• Assistant Examiner(s): Morales, Jon-Eric C.
• Application Number:
  US12/144,351
• Publication Number:
  US 20090005828A1
• Time in Patent Office: 1,282 Days
• Field of Search: 607/9, 607/30, 607/17
• US Class Current: 607/9
• CPC Class Codes: A61N 1/3622 comprising two or more electrodes co-operating with different heart regions
• CPC Class Codes: A61N 1/3956 Implantable devices for applying electric shocks to the heart, e.g. for cardioversion

Abstract

An implantable medical device is provided that comprises a pulse generator that provides atrial and ventricular pacing pulses on demand. The pulse generator times delivery of the ventricular pacing pulses based on an AV pacing interval. The device also includes an AV hysteresis module that extends the AV interval from a base AV interval to an extended AV interval to promote intrinsic heart activity. A refractory module establishes a PVARP interval equal to base PVARP interval following at least one of the ventricular pacing pulses. The refractory module lengthens the PVARP interval by adding a PVARP extension to a base PVARP interval to provide an extended PVARP interval. The device further includes a reentrant conduction detector that identifies an intrinsic reentrant tachycardia having a retrograde P wave occurring during the PVARP extension, based on one or more of i) a retrograde P wave, ii) intrinsic R waves sensed over N cardiac cycles at an R to R interval above a rate threshold and iii) one or more of PR and RP intervals that exceed PR and RP thresholds.

Claims

1. An implantable medical device, comprising:

a pulse generator configured to provide atrial and ventricular pacing pulses on demand, the pulse generator timing delivery of the ventricular pacing pulses based on an AV pacing interval;

an AV hysteresis module that extends an AV interval from a base AV interval to an extended AV interval to promote intrinsic heart activity;

a refractory module that establishes a PVARP interval equal to a base PVARP interval following at least one of the ventricular pacing pulses, the refractory module lengthening the PVARP interval by adding a PVARP extension to the base PVARP interval to provide an extended PVARP interval; and

a reentrant conduction detector identifying an intrinsic reentrant tachycardia based, in part, on a retrograde P wave occurring during the PVARP extension of the extended PVARP interval.

2. The device of claim 1, wherein the reentrant conduction detector identifies the intrinsic reentrant tachycardia based on intrinsic R waves sensed over N consecutive cardiac cycles at an R to R interval above a rate threshold.

3. The device of claim 1, wherein the reentrant conduction detector identifies the intrinsic reentrant tachycardia based on an intrinsic QRS complex having at least one of PR and RP intervals that exceed corresponding PR and RP thresholds.

4. The device of claim 1, wherein the AV hysteresis module restores the AV interval to equal the base AV interval and the refractory module restores the PVARP interval to the base PVARP interval responsive to delivery of a corrective therapy.

5. The device of claim 1, further comprising a therapy control module that directs the pulse generator to provide a corrective therapy responsive to the reentrant conduction detector identifying the intrinsic reentrant tachycardia.

6. The device of claim 5, wherein the therapy control module is configured to deliver the at least one of the ventricular pacing pulses as the corrective therapy timed to follow the retrograde P wave by a delay less than the AV pacing interval.

7. The device of claim 5, wherein the therapy control module is configured to cause the pulse generator to deliver the at least one of the ventricular pacing pulses, during the extended AV interval in connection with the corrective therapy.

8. The device of claim 5, wherein the therapy control module is configured to cause the pulse generator to repeat the corrective therapy on at least two successive cardiac cycles.

9. The device of claim 5, wherein the therapy control module is configured to cause the pulse generator to repeat the corrective therapy during a programmable number N of consecutive cardiac cycles.

10. The device of claim 1, where the intrinsic reentrant tachycardia is one of AV nodal reentrant tachycardia (AVNRT) and AV reentrant tachycardia (AVRT).

11. A method for managing an arrhythmia, comprising:

providing atrial and ventricular pacing pulses on demand, the ventricular pacing pulses being delivered based on an AV pacing interval;

extending an AV interval from a base AV interval to an extended AV interval;

establishing a PVARP interval equal to a base PVARP interval following at least one of the ventricular pacing pulses;

lengthening the PVARP interval by adding a PVARP extension to the base PVARP interval to provide an extended PVARP interval; and

identifying an intrinsic reentrant tachycardia based on a retrograde P wave occurring during the PVARP extension of the extended PVARP interval.

12. The method of claim 11, wherein the identifying operation identifies the intrinsic reentrant tachycardia based on intrinsic R waves sensed over N consecutive cardiac cycles at an R to R interval above a rate threshold.

13. The method of claim 11, wherein the identifying operation identifies the intrinsic reentrant tachycardia based on an intrinsic QRS complex having at least one of PR and RP intervals that exceed corresponding PR and RP thresholds.

14. The method of claim 11, further comprising restoring the AV interval to equal the base AV interval and the PVARP interval to equal the base PVARP interval responsive to delivery of a corrective therapy.

15. The method of claim 11, further comprising determining that a PR interval exceeds a PR threshold for a number of N consecutive cardiac cycles and, in response thereto, restoring the PVARP interval to equal to the base PVARP interval.

16. The method of claim 11, further comprising providing a corrective therapy when the intrinsic reentrant tachycardia is identified.

17. The method of claim 16, wherein the providing of the corrective therapy comprises delivering the at least one of the ventricular pacing pulses timed to follow the retrograde P wave by a delay less than the AV pacing interval.

18. The method of claim 16, further comprising delivering the at least one of the ventricular pacing pulses, during the extended AV interval, in connection with the corrective therapy.

19. The method of claim 16, further comprising repeating the corrective therapy during at least two successive cardiac cycles.

20. The method of claim 16, further comprising repeating the corrective therapy during a programmable number of N consecutive cardiac cycles.

21. The method of claim 11, where the intrinsic reentrant tachycardia event is one of AV nodal reentrant tachycardia (AVNRT) and AV reentrant tachycardia (AVRT).